Related Experiment Video
Updated: Aug 11, 2026

Development of a Unilaterally-lesioned 6-OHDA Mouse Model of Parkinson's Disease
Published on: February 14, 2012
Agonist and antagonist actions of lisuride on dopamine neurons: electrophysiological evidence
1Department of Neurosciences, University of Cagliari, Italy.
Abstract:
The effect of lisuride (LIS) on the firing rate of A9 dopamine (DA) neurons in chloral-hydrate anesthetized and unanesthetized (paralyzed) rats was compared. In both preparations, the microiontophoretic application of LIS onto DA cell bodies consistently inhibited the electrical activity of the neurons. On the other hand, the effect of intravenous LIS differed in the two preparations. In anesthetized rats LIS (10-100 micrograms/kg) inhibited in a dose-related manner the firing rate of most DA neurons tested, whereas in unanesthetized rats LIS produced a dose-related increase in firing rate. The latter effect was transient, subsiding within 5 min, and was followed by the return of firing rate to baseline or slightly below it. Irrespective of the animal preparation, after the initial effect of LIS had subsided, DA neurons became totally insensitive to additional doses of LIS, to apomorphine and haloperidol. Such an insensitivity of DA neurons was present 1 to 6 but not 24 h after LIS (0.2 mg/kg, subcutaneously) treatment. A hypothesis is proposed to explain the different effects of LIS.
Related Concept Videos
Neurochemical Transmission: Sites of Drug Action
Adrenergic Agonists: Indirect-Acting Agents
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral bioavailability, and...
Drugs Affecting Neurotransmitter Release or Uptake
Drugs Affecting Neurotransmitter Synthesis
Antipsychotic Drugs: Typical and Atypical Agents
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...

